MedTrace Logo

Otrivine: Quality of Life (QoL) Impact in a Real-World Setting

NCT05556148 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 136

Last updated 2024-05-17

Study results available
· View outcomes & findings →

Summary

This study is designed to generate real world data from participants with nasal congestion acquired from common cold following treatment with a marketed nasal spray. The main purpose of this study is to evaluate the effectiveness of a nasal spray on quality of life (QoL) factors.

Conditions

  • Common Cold

Interventions

DRUG

Otrivine Congestion Relief

0.1% Nasal Spray (Xylometazoline Hydrochloride)

Sponsors & Collaborators

  • HALEON

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-07
Primary Completion
2022-12-20
Completion
2022-12-20

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05556148 on ClinicalTrials.gov